Pinsent Masons Advises Accord Healthcare in Exclusive Licence Agreement with Myovant Sciences to Commercialise ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
14 Jun 2022 | 03:35 pm |
Pinsent Masons represented Accord Healthcare Ltd in an exclusive license agreement with Myovant Sciences to commercialise relugolix, Myovant’s advanced hormone-sensitive prostate cancer treatment, under the trade name ORGOVYX® in the European Economic Area, United Kingdom, Switzerland and Turkey.
Under the terms of the agreement, Myovant will receive an upfront payment of US$50 million, and is eligible to receive milestones which could total up to a further US$90.5 million. Myovant will continue to lead the global development of relugolix and provide initial product supply to Accord. Accord will be responsible for certain local clinical development, all commercialization for its territories, and has the option to manufacture relugolix in the future.
The Pinsent Masons transactions team was led by Life Sciences Transactions partner Gina Bicknell, with primary support from solicitor Kiah York and legal director Mario Subramaniam.
Latest press releases
Show me all press releasesPinsent Masons advises Ghelamco on a €285m transaction in the Polish office market
Multinational law firm Pinsent Masons has advised developer Ghelamco on the €285 million sale of The Bridge, a landmark Warsaw office tower.
Pinsent Masons advises Manchester Storm on return to AO Arena
Multinational law firm Pinsent Masons is advising Manchester Storm on its move to the AO Arena, helping secure the UK ice hockey club's return to the arena it last called home in 2002.
Pinsent Masons strengthens IP offering with new patent attorney partner Fred Nicolle in London
Multinational law firm Pinsent Masons has appointed Fred Nicolle as a partner in its Intellectual Property (IP) team in London, strengthening the firm's European patents and life sciences offering.
People who viewed this press release also viewed
Show me all press releasesPinsent Masons strengthens IP offering with new patent attorney partner Fred Nicolle in London
Multinational law firm Pinsent Masons has appointed Fred Nicolle as a partner in its Intellectual Property (IP) team in London, strengthening the firm's European patents and life sciences offering.
Pinsent Masons advises Horizon 3 Healthcare on investment in Xeltis
Multinational law firm Pinsent Masons has advised Horizon 3 Healthcare as lead investor in an additional €20.5 million funding round for Xeltis, a clinical-stage medtech company developing transformative implantable medical devices.
Pinsent Masons elects John Maciver as Senior Partner
Multinational law firm Pinsent Masons has elected John Maciver as Senior Partner.
For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on
Location contacts
Europe: [email protected]
Asia: [email protected]
Middle East: [email protected]
Australia: [email protected]